GENMAB A/S -SP ADR (GMAB)
US3723032062 - ADR
GENMAB A/S -SP ADR
NASDAQ:GMAB (7/26/2024, 7:00:01 PM)
After market: 28.38 0 (0%)28.38
+0.25 (+0.89%)
Company Profile
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Company Info
GENMAB A/S -SP ADR
Carl Jacobsens Vej 30
KOEBENHAVN V 1560
P: 4570202728
CEO: Jan G. J. van de Winkel
Employees: 2286
Website: https://www.genmab.com/
GMAB News
12 days ago - ChartmillInvestors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.GENMAB A/S -SP ADR (NASDAQ:GMAB) is showing decent growth, but is still valued reasonably.
a month ago - Genmab A/SEpcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphomaa month ago - Genmab A/SEPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)a month ago - Market News VideoGenmab is Now Oversold (GMAB)a month ago - InvestorPlace7 Biotech Stocks to Buy on the Dip: June 2024With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.
a month ago - Market News VideoInteresting GMAB Call Options For February 2025GMAB Twits
Here you can normally see the latest stock twits on GMAB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
